EluciTx · 合澄生物
Clarity against complex infection.
以科学的澄明，应对感染的复杂
EluciTx is a research-driven biopharmaceutical company focused on anti-infectives. We work on the unmet clinical needs of drug-resistant, difficult-to-treat and recurrent bacterial and fungal infections, combining artificial intelligence with pharmaceutical science to explore safer, more effective and more accessible treatment options.
Unmet need
Infection is still an unsolved problem
Antimicrobial resistance is recognised by the World Health Organization as one of the leading threats to global public health. The burden of bacterial and fungal infections keeps rising while the number of treatment options grows slowly.
Resistance keeps rising
Carbapenem-resistant Gram-negative bacteria, azole-resistant Aspergillus and multidrug-resistant Candida auris are spreading worldwide, increasing the risk that first-line therapy fails.
Few drug classes to rely on
For decades, clinicians have had only a handful of systemic antifungal classes, and few antibacterials with genuinely new mechanisms have reached the clinic.
A narrow window for treatment
Delayed diagnosis, drug toxicity and interactions, and limits on dosing routes and tissue penetration leave high-risk patients caught between waiting for confirmation and treating empirically.
Our approach
Two complementary research routes
Artificial intelligence to accelerate the discovery of new candidate molecules, and evidence-based optimisation of combination regimens to bring clinical value to the bedside sooner.
AI-enabled anti-infective discovery platform
Integrating activity, toxicity and structural data, generating candidates through computational design and screening, validating them experimentally and feeding results back into a closed loop from design to candidate optimisation.
Learn more →Combination and regimen optimisation of approved drugs
Using mechanistic synergy and pharmacokinetic/pharmacodynamic evidence to optimise how approved drugs are combined and dosed, improving efficacy, lowering toxicity and delaying resistance on an established safety foundation.
Learn more →Our purpose
Mission and vision
Mission
To provide safer, more effective and more accessible treatment options for patients with drug-resistant and difficult-to-treat infections.
Vision
To become a trusted partner in anti-infective drug discovery and development, so that every infection can be met with a clear and effective response.
News
Latest news
-
EluciTx incorporated in Beijing
On 25 November 2025, Beijing EluciTx Biopharmaceutical Technology Co., Ltd. (合澄生物) was incorporated in Beijing to develop new anti-infective medicines.
Contact
We welcome conversations with clinical and academic partners
If you work on the clinical, research or industry front line of infectious disease and would like to discuss unmet needs, joint research or collaborative development, please get in touch.